Vineti is a commercial cloud-based platform that expands patient access to life-saving cells and gene therapies. This company was founded by Razmik Abnous, Amy DuRoss, Malek Faham, Heidi Hagen, Stephen Ting in 2016 and is headquartered in San Francisco, CA. Vineti's software solution Personalized Therapy Management (patent pending) automates patient-centric supply chains for a wide range of advanced therapies, in all phases of clinical development and commercial operations.
Funding Date | Share Class | Amount Raised | Price per Share | Post-Money Valuation | Key Investors | |
---|---|---|---|---|---|---|
10/13/2020 | Series C-1 | $31,162.00 | $xx.xx | $216.51MM | Canaan Partners, Cardinal Health, Casdin Capital, Hive Ventures, Lifeforce Capital, Marc Benioff, Mckesson Ventures, Novartis Pharma Ag, Section 32, Threshold Ventures | |
Price per Share
$xx.xx
Shares Outstanding
3,116,232
Liquidation Pref Order
1
Liquidation Pref As Multiplier
1.0x
Conversion Ratio
1.0x
Dividend Rate
0.0%
Cumulative
Non-cumulative
Participating
Non-participating
Participation Cap
--
Key Investors
Canaan Partners, Cardinal Health, Casdin Capital, Hive Ventures, Lifeforce Capital, Marc Benioff, Mckesson Ventures, Novartis Pharma Ag, Section 32, Threshold Ventures
|
||||||
10/13/2020 | Series C-2 | $94,476.00 | $xx.xx | $216.51MM | Canaan Partners, Cardinal Health, Casdin Capital, Hive Ventures, Lifeforce Capital, Marc Benioff, Mckesson Ventures, Novartis Pharma Ag, Section 32, Threshold Ventures | |
Price per Share
$xx.xx
Shares Outstanding
9,447,595
Liquidation Pref Order
1
Liquidation Pref As Multiplier
1.0x
Conversion Ratio
1.0x
Dividend Rate
0.0%
Cumulative
Non-cumulative
Participating
Non-participating
Participation Cap
--
Key Investors
Canaan Partners, Cardinal Health, Casdin Capital, Hive Ventures, Lifeforce Capital, Marc Benioff, Mckesson Ventures, Novartis Pharma Ag, Section 32, Threshold Ventures
|
||||||
10/13/2020 | Series C | $60MM | $xx.xx | $216.51MM | Canaan Partners, Cardinal Health, Casdin Capital, Hive Ventures, Lifeforce Capital, Marc Benioff, Mckesson Ventures, Novartis Pharma Ag, Section 32, Threshold Ventures | |
Price per Share
$xx.xx
Shares Outstanding
35,947,511
Liquidation Pref Order
1
Liquidation Pref As Multiplier
1.0x
Conversion Ratio
1.0x
Dividend Rate
0.0%
Cumulative
Non-cumulative
Participating
Non-participating
Participation Cap
--
Key Investors
Canaan Partners, Cardinal Health, Casdin Capital, Hive Ventures, Lifeforce Capital, Marc Benioff, Mckesson Ventures, Novartis Pharma Ag, Section 32, Threshold Ventures
|
||||||
04/16/2018 | Series B | $33.5MM | $xx.xx | $48.7MM | Canaan Partners, Casdin Capital, Ge Ventures, Lifeforce Capital, Section 32, Threshold Ventures | |
Price per Share
$xx.xx
Shares Outstanding
33,070,086
Liquidation Pref Order
1
Liquidation Pref As Multiplier
1.0x
Conversion Ratio
1.0x
Dividend Rate
0.0%
Cumulative
Non-cumulative
Participating
Non-participating
Participation Cap
--
Key Investors
Canaan Partners, Casdin Capital, Ge Ventures, Lifeforce Capital, Section 32, Threshold Ventures
|
||||||
06/22/2017 | Series A | $14.09MM | $xx.xx | $28.18MM | Ge Ventures, Lifeforce Capital, Mayo Clinic Ventures, Threshold Ventures | |
Price per Share
$xx.xx
Shares Outstanding
5,123,423
Liquidation Pref Order
1
Liquidation Pref As Multiplier
2.0x
Conversion Ratio
2.0x
Dividend Rate
0.0%
Cumulative
Non-cumulative
Participating
Non-participating
Participation Cap
--
Key Investors
Ge Ventures, Lifeforce Capital, Mayo Clinic Ventures, Threshold Ventures
|